Nucleai
Overview
Nucleai is an AI-powered spatial biology platform designed to analyze complex tissue images and extract insights for drug development and diagnostics, primarily in oncology. The platform is intended for use by pharmaceutical companies, biopharmaceutical firms, and clinical research institutions. It aims to support translational research, clinical development, and companion diagnostic development.
- What it does: Nucleai’s technology uses advanced spatial AI methods to analyze and interpret cellular interactions within patient biopsies. It ingests images from various modalities, including H&E, IHC, multiplex immunofluorescence (mIF), and spatial transcriptomics. The platform then conducts spatial analysis to optimize biomarker scoring, determine biomarker prevalence and mechanism of action (MoA), and predict response to therapy.
- Who it is for: The tool is primarily for researchers and clinicians involved in oncology and immunology drug development. This includes professionals in translational pathology, digital pathology, diagnostics, precision medicine, and basic research/academia.
- How it fits a clinical or practice workflow: Nucleai’s platform can integrate with Laboratory Information Management Systems (LIMS) and Laboratory Management Systems (LMS) for real-time data sharing and on-demand AI analysis to augment clinicians’ review of diagnostic pathology cases. It can streamline patient eligibility assessments for clinical trials and assist in developing companion diagnostics. The platform also offers an end-to-end mIF analytics workflow, from image ingest to structured outputs for downstream spatial analysis.
- Notable capabilities: The platform offers automated normalization and cell segmentation across multiple stainers, AI-driven cell typing and marker positivity, and standardized, exportable cell and image-level outputs. It can analyze spatial features to explain the mechanism of action and biological phenomena, and leverage spatial analysis to predict outcomes, genomic status, and protein signatures. Nucleai has also developed a deep learning model to automate spatial proteomics, which is designed to rapidly analyze dozens of protein markers in a single image.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-Driven Spatial Biomarker Analysis
- Multimodal Image Ingestion (H&E, IHC, multiplex immunofluorescence, spatial transcriptomics)
- Advanced Spatial Analysis
- Biomarker Discovery & Validation
- Biomarker Scoring
- Genomic Biomarker Screening
- Mechanism of Action (MoA) Data Enrichment
- Companion Diagnostics Development
- Prediction of Therapy Response
Use Cases
- Powering Drug Development
- Translational Research to Diagnostics
- Clinical Trial Patient Selection
- Optimizing Biomarker Scoring
- Determining Biomarker Prevalence and MoA
- Predicting Response to Therapy
What Physicians Need to Know
Physicians can leverage Nucleai's AI-powered spatial biology platform to gain deeper insights into the tumor microenvironment, enabling more precise patient stratification and personalized treatment strategies, especially for complex oncology cases. The platform's ability to analyze multiplexed samples with high accuracy and integrate various data modalities can aid in identifying patients most likely to respond to specific therapies, thereby optimizing clinical trial participation and improving treatment outcomes.
Nucleai's platform is designed for integration with various imaging modalities (H&E, IHC, multiplex immunofluorescence, spatial transcriptomics) and is agnostic to staining and scanning platforms. They have established partnerships for systems integration with Laboratory Information Management Systems (LIMS) and Laboratory Management Systems (LMS) for real-time data sharing and on-demand AI analysis. Collaborations with digital pathology companies like Proscia aim to integrate Nucleai's predictive biomarker technology into enterprise pathology platforms.
Details
| Category | Drug Discovery & Research, Lab & Diagnostics, Pathology AI |
| Pricing |
Unknown
|
| Deployment | Cloud-based platform. |
| Mobile App | None |
| Target Size | Pharmaceutical companies, biopharmaceutical firms, and clinical research institutions. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Unknown AI-estimated Nucleai's technology is used for research and drug development, and is part of clinical trial patient selection. There is no indication of FDA clearance for diagnostic or clinical use of Nucleai's platform itself. Other companies named 'NucleusHealth' or 'Nucleus.io' have received FDA 510(k) clearance for medical image management platforms, but this is a different entity. |
| SOC 2 | Unknown AI-estimated |
| GDPR | Unknown AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Gastroenterology, Oncology, Pathology |
Social Proof
| Customers | unknown |
| Notable | Collaborations with over 60% of the top 20 biopharma companies. Partners include the University of Glasgow and Bio-Techne. |
What the Web Says
Nucleai is an AI-powered spatial biology company focused on accelerating drug development and improving patient care, particularly in oncology and immunology. Their platform analyzes complex cellular interactions in tissue samples to predict therapeutic outcomes and identify predictive biomarkers. The technology aims to transform traditional biopsy analysis into AI-guided action plans, reducing the time from tissue to insight from months to weeks.
Overall: PositiveStrengths
- Accelerates drug development and biomarker discovery.
- Improves diagnostic accuracy and treatment strategies.
- Provides insights into the tumor microenvironment and cellular relationships.
- Offers scalable, reproducible, and automated workflows for large-scale studies.
- First spatial AI tool used by pathologists for clinical trial patient selection directly connected to a drug development program.
- Reduces tissue-to-insight timelines from months to weeks.
Limitations
- Limited public reviews available from physicians, healthcare IT, or tech reviewers specifically for Nucleai (nucleai.ai).
- Some general concerns exist regarding patient perception of physicians using AI, with some patients viewing them as less competent or trustworthy.
- Potential for overwhelming content and difficulty identifying relevant reviews on platforms like Capterra (general AI software).
- General limitations of current AI techniques, such as interpretability issues and the need for large amounts of annotated data.
- High technical burden and limited scalability in traditional multiplex imaging analysis, which Nucleai aims to solve.
Based on reviews from: G2, Nucleai.ai, Drug Discovery and Development, pharmaphorum, Ctech, Built In Chicago, Capterra, Reddit, PMC - NIH, Radiology Business, Stanford Medicine
Last updated: 2026-07-05
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Nucleai
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Nucleai.
Nucleai Unlocking Spatial Biology
Nucleai
Nucleai Academy: AI Spatial Biomarkers & Diagnostics for Antibody-Drug Conjugates (ADCs)
Nucleai
Nucleai Academy: Spatial AI Biomarkers: The Ideal Companions for Next-Gen Cancer Treatments
Nucleai
Nucleai Demo
Nucleai
Nucleai Academy: From Images to Spatial Biological Features: How Errors Percolate
Nucleai
Frequently Asked Questions
Investors who backed Nucleai
Funded through the company that built this tool.
